Charles River Laboratories International (NYSE:CRL) Upgraded at Redburn Atlantic

Redburn Atlantic upgraded shares of Charles River Laboratories International (NYSE:CRL) from a sell rating to a neutral rating in a report issued on Monday, MarketBeat Ratings reports. Redburn Atlantic currently has $188.00 price target on the medical research company’s stock.

A number of other research firms have also recently commented on CRL. Morgan Stanley cut their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Finally, TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Stock Up 2.1 %

Charles River Laboratories International stock opened at $167.79 on Monday. Charles River Laboratories International has a 1-year low of $150.79 and a 1-year high of $275.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market cap of $8.58 billion, a PE ratio of 1,118.61, a P/E/G ratio of 4.54 and a beta of 1.45. The stock’s fifty day moving average is $170.06 and its two-hundred day moving average is $186.32.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period last year, the firm earned $2.46 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.1% on a year-over-year basis. On average, sell-side analysts expect that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction on Thursday, February 20th. The stock was acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Institutional investors have recently modified their holdings of the company. Versant Capital Management Inc boosted its stake in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares in the last quarter. Optiver Holding B.V. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter worth approximately $37,000. Finally, GeoWealth Management LLC boosted its stake in shares of Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after acquiring an additional 190 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).